Meeting
2021 ASCO Annual Meeting
A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
Authors
Michael J. Morris
Memorial Sloan Kettering Cancer Center, New York, NY
Michael J. Morris , Ronald De Wit , Nicholas J. Vogelzang , Scott T. Tagawa , Celestia S. Higano , Paul Hamberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT03574571
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS5091)
DOI
10.1200/JCO.2021.39.15_suppl.TPS5091
Abstract #
TPS5091
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
First Author: Michael J. Morris
Poster
2019 Genitourinary Cancers Symposium
A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
First Author: Michael J. Morris
Poster
2023 ASCO Genitourinary Cancers Symposium
Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history.
First Author: Alice Bernard-Tessier
Poster
2020 Genitourinary Cancers Symposium
Phase III study of pembrolizumab (pembro) plus enzalutamide (enza) versus placebo plus enza for metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-641.
First Author: Julie Nicole Graff